NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $10,155 | -72.2% | 17,050 | -73.1% | 0.00% | – |
Q2 2023 | $36,474 | -81.1% | 63,411 | +343.2% | 0.00% | – |
Q4 2021 | $193,000 | -26.3% | 14,309 | -1.8% | 0.00% | – |
Q3 2021 | $262,000 | +12.4% | 14,568 | +7.4% | 0.00% | – |
Q2 2021 | $233,000 | -30.2% | 13,564 | -18.8% | 0.00% | – |
Q1 2021 | $334,000 | +63.7% | 16,710 | +39.1% | 0.00% | – |
Q4 2020 | $204,000 | -16.4% | 12,010 | +74.9% | 0.00% | – |
Q2 2019 | $244,000 | -0.8% | 6,868 | -6.3% | 0.00% | – |
Q1 2019 | $246,000 | -3.1% | 7,331 | -5.2% | 0.00% | – |
Q4 2018 | $254,000 | -93.6% | 7,736 | -88.1% | 0.00% | -100.0% |
Q3 2018 | $3,971,000 | +8348.9% | 65,136 | +6499.4% | 0.01% | – |
Q2 2018 | $47,000 | -56.9% | 987 | -8.3% | 0.00% | – |
Q1 2018 | $109,000 | +113.7% | 1,076 | +25.4% | 0.00% | – |
Q4 2017 | $51,000 | +5000.0% | 858 | +946.3% | 0.00% | – |
Q4 2016 | $1,000 | – | 82 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |